key: cord-1021711-rjuo7tfv
authors: Johnson, Justin E.; McGuone, Declan; Xu, Mina L.; Jane-Wit, Dan; Mitchell, Richard N.; Libby, Peter; Pober, Jordan S.
title: COVID Coronary Vascular Thrombosis: Correlation with Neutrophil but not Endothelial Activation
date: 2021-09-29
journal: Am J Pathol
DOI: 10.1016/j.ajpath.2021.09.004
sha: 2c5e5c41e453a3c3ba172d9d74ebddd9645ad515
doc_id: 1021711
cord_uid: rjuo7tfv

Severe COVID-19 infection increases the risk of myocardial injury that contributes to mortality. We used multiparameter immunofluorescence to examine extensively heart autopsy tissue of 7 patients who died of COVID-19 compared to 12 control specimens, some with and some without cardiovascular disease. Consistent with prior reports, we found no evidence of viral infection or lymphocytic infiltration indicative of myocarditis but did observe frequent and extensive thrombosis in large and small vessels in the hearts of the COVID cohort, findings that were infrequent in controls. The endothelial lining of thrombosed vessels typically lacked evidence of cytokine-mediated endothelial activation, assessed as nuclear expression of transcription factors p65 (RelA), pSTAT1, or pSTAT3 or evidence of inflammatory activation assessed by expression of intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), tissue factor, or von Willebrand factor (VWF). Intimal EC lining was also generally preserved with little evidence of cell death or desquamation. In contrast, there were frequent markers of neutrophil activation within myocardial thrombi of COVID-infected patients including neutrophil-platelet aggregates, neutrophil-rich clusters within macrothrombi, and evidence of neutrophil extracellular trap (NET) formation. These findings point to alterations in circulating neutrophils rather than the endothelium as contributors to the increased thrombotic diathesis in the hearts of COVID-19 patients.

Severe COVID-19 infection increases the risk of myocardial injury that contributes to mortality. We used multiparameter immunofluorescence to examine extensively heart autopsy tissue of 7 patients who died of COVID-19 compared to 12 control specimens, some with and some without cardiovascular disease. Consistent with prior reports, we found no evidence of viral infection or lymphocytic infiltration indicative of myocarditis but did observe frequent and extensive thrombosis in large and small vessels in the hearts of the COVID cohort, findings that were infrequent in autoimmune T cell-mediated injury resulting in myocarditis; autoantibody-mediated injury through complement activation and/or antibody-dependent cellular cytotoxicity 11 .

However, numerous autopsy studies have rarely detected viral protein or RNA within the heart despite evidence of abundant virus presence in the lungs of the same patients 12 . Post mortem examination has also rarely revealed multifocal or diffuse myocarditis along with complement and antibody deposition [12] [13] [14] . Rather, thrombosis of micro and macro coronary vessels has most consistently charactered the heart of individuals who succumbed to COVID-19 [14] [15] [16] . The underlying cause of this thrombotic diathesis in the hearts of severe COVID-19 patients is unsettled but has been attributed to either alterations in blood composition and/or pathological changes of the endothelial lining of the vasculature 17 . This study examined heart tissues from seven autopsies of COVID patients performed early in the pandemic before anticoagulation was commonly administered and compared these specimens to twelve COVID negative controls, with and without heart disease, using multiparameter fluorescence microscopy to analyze J o u r n a l P r e -p r o o f the composition of thrombosed vessels. Our data show that alterations in endothelium do occur but are uncommon and do not generally colocalize with sites of thrombosis, whereas the presence of activated circulating neutrophils are routinely observed in the thrombi of patients with severe SARS-CoV-2 disease.

The COVID cohort consists of 7 patients, 4 males and 3 females, who were positive for SARS CoV-2 infection by RT-PCR with ages ranging from 50-94 (Table 1 ). All patients had severe pneumonia. One patient had a sudden cardiac arrest outside of hospital, two patients developed sepsis, and one patient had recurrent acute leukemia with thrombocytopenia. Length of hospitalization ranged from 2-13 days (Supplement Table   S1 ). The COVID negative controls consist of 12 patients, 8 males and 4 females, including 6 patients with pre-existing cardiac disease. Multiple sections from 2 randomly selected areas of the left ventricle were examined for each patient and control. Vector RL-1061, 1062) in same blocking solution for 1hr at room temperature. All antibodies were validated using human tonsils or autopsy heart tissues with myocarditis, sepsis, or myocardial infarction. Secondary only controls were used to ensure specificity of primary antibody binding.

In some instances to colocalize multiple fluorescent signals on the same field we employed a cyclic IF method that involves repeated staining and imaging of the same tissue section with quenching of the fluorescent signal between cycles and using directly conjugated antibody 18 . Briefly, coverslips were placed on slides using PBS with J o u r n a l P r e -p r o o f 10% glycerol. After imaging, coverslips were removed by placing slides in container of PBS for 30 minutes. Sections were then bleached in PBS with 3% H2O2 and NaOH to quench fluorescence. Slides were washed 3 times, then conjugated antibodies were added overnight. Images were recorded at each step and then brought into spatial alignment for colocalization of staining patterns using ImageJ software version 2.1.0/1.53c (Fiji, https://fiji.sc, last accessed August 23, 2021) 19 .

Random single and large (100+) tiled images were taken at 20x or, when possible, the whole tissue imaged at 10X. Fluorescence was normalized to vessel or tissue area.

Ulex and DAPI colocalization was used to determine ROIs of EC nuclei for quantification of pSTAT1, pSTAT3, and p65 fluorescence. ImageJ was used to process and measure fluorescence of tissue.

Data are expressed as mean ± SEM. Statistical analyses were performed using GraphPad Prism software. The Mann-Whitney test was used to make statistical comparisons between two groups. A P value of less than or equal to 0.05 was considered statistically significant.

Thrombosis is the most common pathologic finding in heart autopsy specimens of COVID cohort J o u r n a l P r e -p r o o f Consistent with prior reports 12 we observed extensive micro and macrothrombi in 6/7 of the COVID cohort ( Figure 1 ) and did not detect SARS-CoV-2 spike or nucleocapsid antigen indicative of active infection, evidence of multifocal lymphocytic infiltrates indicative of myocarditis, or complement deposition on endothelium indicative of antibody-mediated vasculitis (Supplemental Figure S1 ). The only patient without evident thrombosis had a diagnosis of acute lymphocytic leukemia with progressive thrombocytopenia. To quantify the extent of thrombosis, we stained slides of FFPE heart samples using antibodies reactive with platelet protein CD42b and/or fibrinogen.

Based on these stains, COVID patients had a greatly elevated frequency of platelet rich microthrombi per 20x field ( Figure 1A ) and total number of macrothrombi involving both intramyocardial arteries and veins ( Figure 1B) in tissues compared to our COVID negative controls. We also found several multinucleated giant cells that stained with CD42b, consistent with megakaryocytes, within the cardiac vasculature of three patients; such cells were not seen in any controls ( Figure 1C ). Despite the widespread evidence of thrombosis, we did not see evidence of myocyte death or acute inflammation typically associated with myocardial infarction.

To assess if endothelial alterations occur in the context of COVID-19 associated cardiac vascular thrombosis, we examined the vessels of the heart for signs of endothelial cell (EC) injury or activation. EC injury by apoptosis can promote thrombosis through release of microparticles containing pro-coagulative tissue factor or by EC sloughing that can expose platelet-activating collagen 20, 21 . Cytokine-activated J o u r n a l P r e -p r o o f endothelium may also become procoagulant, e.g through synthesis of tissue factor, or platelet adhesive by release of high molecular weight von Willebrand factor 22, 23 .

Evaluation of intimal injury revealed only rare markers of cleavage/activation of caspase 3 in endothelial cells in 1/7 patients (Figure 2A ) unrelated to sites of thrombosis. One patient showed both rare foci of EC denudation with adherent platelets and rare VE-Cadherin+ cell fragments colocalized with platelets ( Figure 2 , B and C). Another patient manifested rare foci of tissue factor expression within the vascular lumen but not colocalized with sites of thrombosis ( Figure 2D ). There was an increased percentage of vessels with VWF luminal staining in three COVID patients, but primarily not coincident with sites of thrombosis ( Figure 2E ). The COVID patient with the highest level of VWF expression, found in ~5% of vessels, was patient 6 who had recently suffered a MI. The sample with the second most frequent localization of VWF was from the patient with ALL who showed no signs of thrombosis.

Next, we sought signs of cytokine-activated signaling pathways in the ECs by assessing both nuclear p65 (Rel A) translocation and STAT protein tyrosine phosphorylation. Nuclear p65, a trigger of IL-1 or TNF signaling, was limited and of no greater frequency in ECs of COVID patients vs. controls ( Figure 2F ). Endothelial pSTAT1 expression, indicative of IFN signaling, was absent in all but one patient who exhibited expression on 0.6% of ECs and none at sites of thrombosis ( Figure 2G) .

Similarly, the percentage of ECs with pSTAT3 expression, indicative of responses to IL-6 family cytokines, did not differ significantly between COVID patients and controls with the notable exception of one COVID patient who showed elevated levels of pSTAT3 expression on 17.5% of ECs ( Figure 2H ). This patient had suffered a cardiac arrest one J o u r n a l P r e -p r o o f day before death. Consistent with a paucity of evidence for endothelial cell responses to cytokines, there was no statistically significant increase in the expression of ICAM-1 ( Figure 2I ) or VCAM-1 ( Figure 2J ) in patients compared to controls along with E-selectin expression (Supplement Figure S2) . The one COVID patient that showed increased VCAM-1 expression was the same patient described above that suffered a recent cardiac arrest. Supplement Table S2 summarizes several of these histological findings.

Thrombosis can also occur due to changes in the composition or activation of various components in the blood. In contrast to the limited findings of endothelial alterations, the composition of thrombi revealed the frequent presence of platelets associated with neutrophils ( Figure 3, A and B ) and many of these neutrophils stained positive for Citrullinated Histone 3 (CitH3), an early step in neutrophil extracellular trap (NET) formation. Eventually, these neutrophils will undergo NETosis which is the expulsion of NETs or structures composed of chromatin, histones, and other internal neutrophil molecules that can bind pathogens or serve as sites of thrombosis. We found evidence of NET formation in neutrophils at sties of thrombi in 4 of the 6 COVID patients with thrombi. Some images suggest NETs that appear to be directly associated with platelets ( Figure 3C ). Neutrophil rich macrothrombi composed of 30% or more neutrophils were also common in COVID but not control specimens (Figure 3, D and E) .

CitH3+ neutrophil only aggregates also localized in vessels ( Figure 3F ). Many of these J o u r n a l P r e -p r o o f neutrophils appeared to have elevated expression levels of p65 (RelA), the significance of which is uncertain but, like NET formation, may reflect an activated state ( Figure 3G ).

This study reports findings that agree with and extend results of prior autopsy series of hearts from patients dying of COVID-19. We found thrombosis of micro and 29 . Our findings agree with and extend these reports and suggest that neutrophils play a very prominent role in thrombosis of the heart in these COVID patients.

Neutrophils may be activated to release NETs by recognition or infection of virus or bacteria, activation by cytokines, or interactions with platelets, complement and/or antibodies 30 . Our data in the heart favor a role of cytokines and platelets in promoting NETs as we found CitH3+ neutrophils in thrombi that were bound to platelets in the absence of virus, antibody, or complement. Minimal endothelial activation in the heart may be preventing neutrophils from entering the heart parenchyma unlike lungs of the same patient. Interestingly, we also found neutrophil aggregates, which may serve as an additional thrombotic stimulus for platelet aggregation leading to larger thrombi.

Heparin therapy commonly administered to COVID-19 patients to block coagulation may also prove to be beneficial in reducing NET-dependent thrombus formation in patients. This negatively charged polymer can interact with positively charged histones released by NETs, rendering them unable to activate platelets and potentiate thrombosis 31 prophylaxis. Analysis of further samples will be required to validate this conclusion. We also recognize that thrombosis in hearts, which do not appear to be sites of viral infection, may be different from the processes occurring in other sites, such as lung or the gut, in which virus and abundant inflammation is present.

In conclusion, our multiparameter analysis of cardiac vessel thrombosis points to activation of circulating neutrophils as the most likely causal event. Alterations in the vessel wall, although seen in some instances, are relatively rare. In light of these findings, reducing neutrophil responses could be an important target for therapeutic intervention.

The frequency of microthrombi per 20X field was quantified in controls and COVID patients. Representative images of microthrombi composed of platelets and/or fibrin (B). The total number of macrothrombi per tissue section was counted by imaging whole tissue at 10X and dividing by tissue area. Representative images of macrothrombi composed of platelets and/or fibrin (C). Image of a megakaryocyte present in heart tissue. CD42b was used to identify platelets; ICAM-1 for vessels. Data represent mean ± SEM. **P< 0.01; ***P<0.001. Scale bars: (A). 50μm, 100μm (B). 50μm, 100μm (C) . 50μm. . (B, C) . Patient tissue images of neutrophil-platelet aggregates and a neutrophil during NETosis, capturing platelets. (D) Neutrophil rich macrothrombi composed of more than 30% neutrophils were counted in entire tissue at 10X. Values were normalized by tissue area. (E, F). Images showing neutrophil macrothrombi and neutrophil aggregates that are CitH3+ in circulation in COVID heart tissue. (G). Image shows neutrophils with increased p65 expression (arrows) in COVID tissue. Myeloperoxidase (MPO) was used to identify neutrophils and Citrullinated histone H3 (CitH3) to identify NET formation. Data represent mean ± SEM. *P<0.05. Scale bars: (B,C,E,F). 50μm (G). 100μm. 

Cardiac Involvement in Patients Recovered From COVID-2019 Identified Using Magnetic Resonance Imaging

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: A meta-analysis

Factors associated with COVID-19-related death using OpenSAFELY

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)

Evaluation of myocardial injury patterns and ST changes among critical and non-critical patients with coronavirus-19 disease

Characterization of Myocardial Injury in Patients With COVID-19

Myocardial injury in hospitalized patients with COVID-19 infection-Risk factors and outcomes

Myocardial injury and COVID-19: Possible mechanisms

COVID-19 and the Heart: A Systematic Review of Cardiac Autopsies

Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations

Microthrombi as a Major Cause of Cardiac Injury in COVID-19: A Pathologic Study

COVID-19-Associated Nonocclusive Fibrin Microthrombi in the Heart

Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series

Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19

Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging

Fiji: an open-source platform for biological-image analysis

Thrombosis and platelets: an update

Apoptotic Vascular Endothelial Cells Become Procoagulant

Interleukin-1 activation of vascular endothelium. Effects on procoagulant activity and leukocyte adhesion

von Willebrand factor and the endothelium

Factor V is an immune inhibitor that is expressed at increased levels in leukocytes of patients with severe Covid-19

On behalf of the CSi: COVID-19 induces a hyperactive phenotype in circulating platelets

A neutrophil activation signature predicts critical illness and mortality in COVID-19

Platelet gene expression and function in patients with COVID-19

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Assessment of Neutrophil Extracellular Traps in Coronary Thrombus of a Case Series of Patients With COVID-19 and Myocardial Infarction

Patients with COVID-19: in the dark-NETs of neutrophils

Immunothrombosis in COVID-19: Implications of Neutrophil Extracellular Traps. Biomolecules 2021

Circulating Histones in Sepsis: Potential Outcome Predictors and Therapeutic Targets

We thank Gregory Tietjen for use of microscope.J o u r n a l P r e -p r o o f